drugset / Trial / NCT00136448
High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)
Non-randomizedSingle-groupOpen-label
Summary
This study will add interleukin-2 (IL-2) to a regimen of post-remission therapy consisting of high-dose ara-C. Patients with AML in first remission will receive 3 cycles of high-dose ara-C followed by continuous infusion and bolus interleukin-2 (IL-2). We, the researchers at the Dana-Farber Cancer Institute, plan to evaluate the immunologic effects of such treatment in these patients.
Timeline
- Start
- 1993-02
- Primary completion
- 2007-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 600000 unknown | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | 810000 unknown | Intravenous |
| Background | Cytarabine | Small molecule | 3000 mg/m2 | — |
| Background | Daunorubicin | Small molecule | 45 mg/m2 | — |